CBIH Announces the Completion of the "Phase of Research and Discovery" for Its Phytotherapy Cancer Scientific Project
HOUSTON, TX -- May 01, 2023 -- InvestorsHub NewsWire
-- CBIH, previously known as CHNC, and trading under the
ticker symbol CHNC,
announces the completion of the stage “research and
discovery” on the strategic framework to develop future clinical
trials of the effectiveness of cannabinoids in the treatment of
Cancer.
In this phase of target identification and validation, CBIH’s
scientific team has developed molecular biology data analysis for
exploring targets and biomarkers in this complex disease with over
200 subtypes. As a result of this research phase, CBIH´s group of
scientists has developed a series of formulation proposals for the
different cancer stages (from I to IV). These formulations include
prototypes of different routes of administration; oral,
oromucousal, sublingual, topical, inhalation, rectal, and vaginal
route.
“The American Cancer Society has projected that the United
States will see 1,958,310 new cancer cases and 609,820
cancer-related deaths in 2023. The figures serve as a call to
action to prioritize cancer control measures and work towards
reducing the burden of cancer on individuals and society,”
according to Dr. José Torres, MD, CBIH National Medical
Director,
“Cannabinoids have the potential to control the microenvironment
surrounding a tumor, which is critical for its growth and spread.
By blocking the receptors and molecules that facilitate the
signaling process, cannabinoids can prevent tumors from sending
signals to neighboring cells that help them grow and proliferate.
One vital biomolecule is called VEGF, which helps tumors get the
blood supply they need to grow. By blocking VEGF, cannabinoids can
stop the tumors from getting blood supply and support our immune
system in fighting off the cancer cells,” says Jennifer Salguero,
Biologist, PhD in Science, Chief of CBIH Research Department.
CBIH expects to advance in new approaches to combat this
persistent and frighteningly escalating global health concern with
this non-clinical development phase. And at the same time,
the company will explore research and development
partnerships, also it will continue advancing in the framework
needed to announce future clinical trials with
cannabinoids.
CBIH will continue to dedicate its human and economic resources
in order to hopefully develop and provide a solution for Cancer
patients worldwide and will announce the conclusion of each stage
with the sole purpose of improving the quality of life of thousands
of people by continuing to create non-traditional medicine in a
traditional world.
To learn more visit: https://www.chnc-hdh.com/
For more information contact us at: info@pharmacologyuniversity.com
817/528-2475 for English
214/733-0868 for Spanish
China Infrastructure Con... (PK) (USOTC:CHNC)
過去 株価チャート
から 5 2024 まで 6 2024
China Infrastructure Con... (PK) (USOTC:CHNC)
過去 株価チャート
から 6 2023 まで 6 2024